About Levocetirizine Dihydrochloride API
Therapeutic Category Respiratory

CAS Number
130018-87-0
API Technology
Synthetic
Dose Form
Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, EUDMF, Korea DMF, CEP Submitted
Mechanism of Action
Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H1-receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs. 6 nmol/L, respectively). The clinical relevance of this finding is unknown.
Indication
XYZAL is a histamine H1-receptor antagonist indicated for:
- The relief of symptoms associated with perennial allergic rhinitis
- The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria
FAQs
Treats symptoms of allergic rhinitis and chronic idiopathic urticaria
Available as oral tablets (5 mg) and oral solution (2.5 mg/5 mL)
Relieves allergy symptoms like runny nose, sneezing, and itching Reduces hives and associated itching
Store at 20°C to 25°C (68°F to 77°F), in a cool, dry place, away from moisture and heat